Profound Medical Corp. (PROF) Stock Price & Analysis
Profound Medical Corp. (PROF) rose 3.81% to USD 6.82 as of June 10, 2026 at 05:35 UTC, according to Nexqual real-time market data.
PROF last closed at USD 6.57; the session ranged USD 6.52–6.87 on volume of 60,707 shares. Market capitalization is $247.82M, with a 52-week range of USD 3.76–8.95 (NCM). Source: Nexqual, June 10, 2026 at 05:35 UTC.
Key Statistics (as of June 10, 2026 at 05:35 UTC)
| Price | USD 6.82 |
|---|---|
| Change | ▲ 3.81% (up) |
| Previous Close | USD 6.57 |
| Open | USD 6.59 |
| Day Range | USD 6.52 – 6.87 |
| 52-Week Range | USD 3.76 – 8.95 |
| Volume | 60,707 shares |
| Market Cap | $247.82M |
| Exchange | NCM |
Technical Analysis (PROF)
Nexqual's technical model rates PROF "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:35 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.77 (neutral) |
| vs SMA50 | Above (USD 6.72) |
| MACD | -0.05 (negative) |
Analyst Ratings (PROF)
Wall Street analysts rate PROF "Strong Buy" based on 5 analysts, with a mean price target of USD 11.14 (range USD 10–12), per Nexqual as of June 10, 2026 at 05:35 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 11.14 |
| High Target | USD 12 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (PROF)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -0.24 |
| Revenue Estimate | $6.53M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.19 vs est -0.25 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.27 ▲ beat |
| 2025-09-30 | USD -0.26 vs est -0.38 ▲ beat |
| 2025-06-30 | USD -0.52 vs est -0.4 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:35 UTC.
Financials & Fundamentals (PROF)
| Total Revenue | $18.81M |
|---|---|
| Revenue Growth (YoY) | +103.60% |
| Gross Margin | +71.08% |
| Operating Margin | -150.29% |
| Profit Margin | -206.76% |
| ROE | -70.59% |
| Debt / Equity | 12.56 |
| Current Ratio | 6.56 |
| Total Cash | $50.30M |
| Total Debt | $7.46M |
| Free Cash Flow | $-22.83M |
Source: Nexqual, June 10, 2026 at 05:35 UTC.
Financial Health Score (PROF)
Nexqual rates Profound Medical Corp.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:35 UTC.
| Growth | Strong — Revenue +45% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $50M cash vs $7M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$23M, burning cash |
| Efficiency | Critical — ROE -71%, ROA -35.5% |
Ownership (PROF)
| Insider Ownership | +4.07% |
|---|---|
| Institutional Ownership | +47.96% |
| Shares Outstanding | 36.34M |
| Float | 34.84M |
| Short % of Float | +6.87% |
Source: Nexqual, June 10, 2026 at 05:35 UTC.
Leadership (PROF)
Profound Medical Corp. is led by Arun Swarup Menawat (age 70), Chairman of the Board & CEO, per Nexqual as of June 10, 2026 at 05:35 UTC.
| Chairman of the Board & CEO | Arun Swarup Menawat (age 70) |
|---|---|
| President | Mathieu Burtnyk (age 43) |
| Chief Financial Officer | Rashed Dewan (age 57) |
Major Backers & Investors (PROF)
Notable institutional backers of Profound Medical Corp. include FIL LTD, Gagnon Securities, LLC, Royce & Associates LP, according to Nexqual as of June 10, 2026 at 05:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FIL LTD | 6.44% |
| Gagnon Securities, LLC | 5.35% |
| Royce & Associates LP | 3.07% |
| Timelo Investment Management Inc. | 3.07% |
| Gagnon Advisors, LLC | 2.65% |
| Letko, Brosseau & Associates Inc. | 2.62% |
| Rosalind Advisors, Inc. | 2.28% |
| Z3 Capital Partners, LLC | 2.25% |
Source: Nexqual, June 10, 2026 at 05:35 UTC.
From Profound Medical Corp.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
- The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.
- It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.
- It operates in Canada, Germany, the United States, China, and Finland.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TELA | TELA Bio, Inc. | USD 0.94 | ▲ 6.25% |
| XGN | Exagen Inc. | USD 4.31 | ▲ 0.47% |
| SIBN | SI-BONE, Inc. | USD 15.53 | ▲ 2.71% |
| APYX | Apyx Medical Corporation | USD 4.86 | ▲ 8.72% |
| KIDS | OrthoPediatrics Corp. | USD 18.49 | ▲ 0.93% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:35 UTC. This page is informational and not investment advice.